Boehringer Ingelheim Markets Novozymes Poultry Probiotics

Jamie Johansen

Boehringer Ingelheim Animal Health and Novozymes announced a strategic collaboration to develop and commercialize probiotics for global poultry production. The parties will focus on developing products for hatcheries. As part of the agreement, Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product for the U.S. poultry industry.

“Boehringer Ingelheim is continuously exploring new science, products and industry categories, to deliver a powerful range of innovative solutions with a focus on customer needs. Poultry producers are looking for improved ways to deliver on the growing global need for sustainable protein,” said George Heidgerken, Global Head of Livestock at Boehringer Ingelheim. “Collaborating with Novozymes enables Boehringer Ingelheim to enter an exciting new segment of products to provide alternatives in an environment that is increasingly challenged by antibiotic bans.”

“We are excited to collaborate with Boehringer Ingelheim to develop a range of probiotic solutions for poultry that will improve sustainability in the industry”, said Susanne Palsten Buchardt, Vice President, Animal Health & Nutrition at Novozymes. “The collaboration is an important step in solidifying Novozymes’ capabilities within probiotics and helping poultry producers deliver greater quantities of safe, affordable protein. Utilizing Boehringer Ingelheim’s close relationships with large-scale producers, Novozymes will gain valuable access to new distribution channels and customers, many of which are seeking sustainable alternatives to antibiotic growth promoters”.

Agribusiness, Animal Health, Boehringer Ingelheim, Chicken, Eggs, Nutrition, Poultry, Probiotics